Search Results

in ovarian cancer: a study of interobserver variability . Gynecol Oncol 1994 ; 55 : 87 – 90 . 9. Gordon AN Fleagle JT Guthrie D . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin

. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol 2001 ; 19 : 3312 – 3322 . 15. Cantu MG Buda A Parma G . Randomized controlled trial of single

Ovarian (PLCO) Cancer Screening randomized controlled trial . JAMA 2011 ; 305 : 2295 – 2303 . 6 Horvath G Jarverud GA Jarverud S Horvath I . Human ovarian carcinomas detected by specific odor . Integr Cancer Ther 2008 ; 7 : 76 – 80

large B-cell lymphoma, Seromucinous ovarian carcinoma, Borderline mucinous ovarian tumor, Borderline serous ovarian tumor). In the remaining 47 patients, 8(17%) were not offered genetic testing, 10 (21%) were either offered genetic testing but it was not

primary appears less likely from a pathologic point of view. Although we contend that a definitive diagnosis would not rely on morphology alone but would require immunohistochemistry, the morphology should have prompted considering ovarian carcinoma as one

-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer—adjuvant chemotherapy in ovarian neoplasm trial . J Natl Cancer Inst 2003 ; 95 : 113 – 125 . 8. Trimbos JB Parmar M Vergote I . International collaborative ovarian

)–positive, triple-negative (estrogen receptor–negative, HER2/neu-negative, progesterone receptor–negative) breast cancer, breast carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, uterine corpus carcinoma, and ovarian cancer

; breast carcinoma; fallopian tube carcinoma; ovarian carcinoma; primary peritoneal carcinoma; uterine corpus carcinoma; and ovarian cancer Institution: City of Hope Comprehensive Cancer Center This phase I trial is studying the side effects and best

, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, and uterine corpus carcinoma Institution: City of Hope National Medical Center This phase I trial evaluates the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of

, ovarian carcinoma, primary peritoneal carcinoma, uterine corpus carcinoma, and ovarian cancer Institution: City of Hope National Medical Center This phase I trial is studying the side effects and best dose of mirvetuximab soravtansine (IMGN853) and